John Mascarenhas, MD

Articles

Dr Mascarenhas on Prior Data Showing the Efficacy of Navtemadlin in R/R Myelofibrosis

December 19th 2024

John Mascarenhas, MD, discusses preclinical and clinical data showing symptom improvement and spleen responses with navtemadlin in myelofibrosis.

Updated Safety and Efficacy Data From the Phase 3 MANIFEST-2 Study of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor Treatment-Naïve Patients With Myelofibrosis

June 21st 2024

This is safety and efﬁcacy update on the MANIFEST-2 trial (NCT02158858), a global, randomized, double-blind, active-control, phase 3 study using pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myeloﬁbrosis.

Dr Mascarenhas on the Use of Selinexor in Myelofibrosis

February 1st 2024

John Mascarenhas, MD, discusses the use of selinexor with ruxolitinib in JAK inhibitor–naive myelofibrosis, highlighting the phase 2 XPORT-MF-044 trial

Dr Mascarenhas on the Potential Utility of Selinexor Plus Ruxolitinib in Myelofibrosis

January 11th 2024

John Mascarenhas, MD, discusses the potential advantages of utilizing selinexor with ruxolitinib in patients with JAK inhibitor–naive myelofibrosis.

Future Perspectives in the Treatment of Polycythemia Vera

September 22nd 2023

John Mascarenhas, MD, and Joe Scandura, MD, PhD, close their discussion by highlighting what to look forward to in the future of polycythemia vera treatment.

Ruxolitinib in the Treatment of PV

September 15th 2023

Key opinion leaders discuss data on the use of ruxolitinib in patients with polycythemia vera.

Influence of Driver Mutations on Response to Ropeginterferon Alpha-2b in Patients with PV

September 15th 2023

Joe Scandura, MD, PhD, explains how a patient with polycythemia vera and driver mutations responds to interferon treatment.

Treatment Approaches for High-Risk Patients With PV

September 8th 2023

Drs Joe Scandura and John Mascarenhas discuss their treatment approaches for high-risk patients with polycythemia vera.

Key Trials in the Treatment of PV

September 8th 2023

Experts review critical trial data in the treatment of patients with polycythemia vera.

Managing Toxicities of Ropeginterferon Alpha-2b in Patients With PV

September 1st 2023

Joe Scandura, MD, PhD, summarizes the toxicity profile of interferon therapy in patients with polycythemia vera.

Managing Toxicities of Hydroxyurea in Patients With PV

September 1st 2023

Drs John Mascarenhas and Joe Scandura review the toxicities seen with the non-specific chemotherapeutic agent hydroxyurea in patients with polycythemia vera.

Factoring Symptom Burden Into Treatment Decision-Making for Patients With PV

August 25th 2023

Joe Scandura, MD, PhD, explains how he considers individual symptom burden when deciding on a treatment regimen for a patient with polycythemia vera.

Reducing Risk of Thrombosis in Patients With PV

August 25th 2023

Key opinion leaders discuss their treatment targets for low- and high-risk patients with polycythemia vera.

Dr Mascarenhas on the Goals of the Phase 1/2 KRT-232-109 Study in Myelofibrosis

August 21st 2023

John Mascarenhas, MD, discusses the goals of the phase 1/2 KRT-232-109 study evaluating the addition of the first-in-class MDM2 inhibitor navtemadlin to ruxolitinib in patients with primary or secondary myelofibrosis and highlights the eligibility criteria of this trial.

Importance of Bone Marrow Biopsy For Diagnosis of PV

August 18th 2023

Experts explain the critical importance of obtaining bone marrow biopsies for accurately diagnosing polycythemia vera.

Typical Presentation of a Patient With PV

August 18th 2023

John Mascarenhas, MD, and Joe Scandura, MD, PhD, detail the typical presentation of a patient with polycythemia vera in their clinical practices.

Dr Mascarenhas on the Rationale for the KRT-232-109 Study in Secondary Myelofibrosis

August 17th 2023

John Mascarenhas, MD, discusses the rationale for adding the first-in-class MDM2 inhibitor navtemadlin to ruxolitinib in patients receiving treatment for primary or secondary myelofibrosis who have previously had suboptimal responses with ruxolitinib.

Reducing Risk of Disease Progression in Patients With PV

August 11th 2023

Dr Joe Scandura discusses how he considers risk of disease progression when during therapeutic decision making for a patient with polycythemia vera.

Risk Assessment in Patients With Polycythemia Vera (PV)

August 11th 2023

Joe Scandura, MD, PhD, reviews how he approaches risk assessment in patients with polycythemia vera and how risk score helps to determine treatment.

Dr Mascarenhas on the Initial Efficacy of Navtemadlin Plus Ruxolitinib in Myelofibrosis

June 23rd 2023

John Mascarenhas, MD, discusses initial clinical activity observed with the addition of the first-in-class MDM2 inhibitor navtemadlin to ruxolitinib in primary or secondary myelofibrosis.